

Global Swine Mycoplasma Hyopneumoniae Vaccine Market Growth 2026-2032

<https://marketpublishers.com/r/G71A0E0E4313EN.html>

Date: July 2026

Pages: 145

Price: US\$ 3,660.00 (Single User License)

ID: G71A0E0E4313EN

Abstracts

The global Swine Mycoplasma Hyopneumoniae Vaccine market size is predicted to grow from US\$ 709 million in 2025 to US\$ 998 million in 2032; it is expected to grow at a CAGR of 5.0% from 2026 to 2032.

Swine Mycoplasma Hyopneumoniae Vaccine is a veterinary biological product used to prevent and control respiratory disease associated with Mycoplasma hyopneumoniae infection in pigs. It is mainly used for active immunization of piglets, nursery pigs, growing-finishing pigs and replacement breeding herds to reduce the risk of swine enzootic pneumonia, coughing, lung lesions, secondary infections and production performance losses. The product category includes inactivated vaccines, live attenuated vaccines, subunit or recombinant vaccines, and dual or multivalent vaccines containing Mycoplasma hyopneumoniae antigen together with antigens such as porcine circovirus type 2. Inactivated vaccines and combination vaccines containing Mycoplasma hyopneumoniae antigen remain the mainstream product forms globally, while live vaccines are mainly used in China and a limited number of regional markets. Key upstream materials include production strains, dedicated culture media, inactivating agents, attenuated-strain culture materials, recombinant antigen expression materials, adjuvants, buffers, stabilizers, freeze-drying protectants, sterile filling materials, glass or plastic vials, rubber stoppers, aluminum caps, labels and cold-chain packaging materials. Downstream customers mainly include large integrated swine producers, commercial pig farms, breeding farms, veterinary service providers, animal health distributors and regional animal disease control procurement channels. The global effective capacity of this product category is estimated at around 1.58 billion doses in 2025, with sales volume of approximately 1.246 billion doses and an average ex-factory price of about USD 0.58 per dose. The industry gross margin in 2025 is estimated at roughly 46%-66%, with multinational brands, dual vaccines, multivalent vaccines and

one-shot immunization products usually positioned at the upper end of the range, while local single vaccines and regional products are more commonly positioned in the middle to lower part of the range.

The Swine *Mycoplasma Hyopneumoniae* Vaccine market has established a mature global application base, with demand mainly supported by the long-term need for respiratory disease control in large-scale swine farms. As pig production continues to move toward group-based, intensive and refined management, producers are placing greater emphasis on stable vaccination programs, herd uniformity, feed conversion improvement and control of secondary infections. These vaccines are widely used in piglet and nursery-stage immunization and have become an important part of basic herd health programs. Current competition is no longer limited to price, but is increasingly shaped by immune efficacy stability, product safety, farm-level technical service capability and the value of integrated disease-control solutions.

Looking ahead, the market will continue to upgrade toward combination vaccines, one-shot immunization and scenario-based vaccination programs, especially products linked with the prevention of porcine circovirus type 2 and other common swine diseases. Large-scale pig producers prefer solutions that reduce the number of injections, lower handling stress, save labor costs and improve compliance with vaccination programs. Products with stronger convenience and broader disease-control value are therefore more likely to receive purchasing preference. Adjuvant systems, antigen purification, strain adaptability, recombinant antigen expression and batch-to-batch consistency will become key directions for product upgrading. Industry competition will gradually shift from traditional single-vaccine competition toward high-quality combination vaccines, differentiated strains and integrated immunization solutions.

The main growth drivers come from the industrialization of pig farming, more refined herd health management, the trend toward reduced antibiotic use and producers' continued pursuit of better production performance. Although *Mycoplasma hyopneumoniae* infection is usually not characterized by acute high mortality, it has a long-term impact on feed conversion, average daily gain, lung lesions and secondary infections, creating hidden economic losses. This makes preventive vaccination more acceptable to large-scale farms. As farm management capabilities improve, vaccine procurement decisions are increasingly based on immune efficacy, technical support, batch consistency and whole-cycle herd health value. Companies with stable supply capacity, strong product portfolios and farm service systems are more likely to gain recognition from large-scale customers.

Key constraints include pork price cycles, fluctuations in farm-level animal health budgets, regional differences in vaccination habits and the difficulty of validating field performance for multivalent vaccines. During periods of weak pork prices, small and medium-sized farms may reduce spending on animal health products, putting short-term pressure on demand. In some regions, reliance on medication, insufficient implementation of basic immunization programs or slower acceptance of new vaccine routes may also limit market penetration. Meanwhile, differences in local epidemic strains, regulatory approval requirements, cold-chain distribution conditions and efficacy comparison among different technology routes add complexity to market expansion. Overall, this is a structurally upgrading market built on a mature demand base, with long-term growth mainly driven by product upgrades, combination vaccine substitution, localized supply and optimized immunization programs for large-scale farms.

LP Information, Inc. (LPI) ' newest research report, the "Swine Mycoplasma Hyopneumoniae Vaccine Industry Forecast" looks at past sales and reviews total world Swine Mycoplasma Hyopneumoniae Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Swine Mycoplasma Hyopneumoniae Vaccine sales for 2026 through 2032. With Swine Mycoplasma Hyopneumoniae Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Swine Mycoplasma Hyopneumoniae Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Swine Mycoplasma Hyopneumoniae Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Swine Mycoplasma Hyopneumoniae Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Swine Mycoplasma Hyopneumoniae Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Swine Mycoplasma Hyopneumoniae Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Swine Mycoplasma Hyopneumoniae Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Swine Mycoplasma Hyopneumoniae Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Inactivated Vaccine

Live Attenuated Vaccine

Others

Segmentation by Vaccine Valency:

Single Vaccine

Dual Vaccine

Others

Segmentation by Dose Pack Size:

Small Pack (Below 20 Doses per Vial)

Medium Pack (20-50 Doses per Vial)

Large Pack (Above 50 Doses per Vial)

Segmentation by Application:

Large-scale Pig Farming Groups

Breeding Pig Farms

Veterinary Service Providers

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Zoetis

Boehringer Ingelheim

Merck Animal Health

Ceva Santé Animale

HIPRA

Bioveta

Vaxxinova

Nisseiken

Kyoto Biken Laboratories

Pulike Biological Engineering

Wuhan Keqian Biology

Qilu Animal Health

Huapai Biotechnology

TianKang Pharmaceutical

Jinyu Bio-technology

Zhaofenghua Bio-technology

Yunnan Biopharmaceutical

Yangzhou Uni-Bio Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Swine Mycoplasma Hyopneumoniae Vaccine market?

What factors are driving Swine Mycoplasma Hyopneumoniae Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Swine Mycoplasma Hyopneumoniae Vaccine market opportunities vary by end market size?

How does Swine Mycoplasma Hyopneumoniae Vaccine break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Swine Mycoplasma Hyopneumoniae Vaccine by Country/Region, 2021, 2025 & 2032
- 2.2 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Type
 - 2.2.1 Inactivated Vaccine
 - 2.2.2 Live Attenuated Vaccine
 - 2.2.3 Others
 - 2.2.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type
 - 2.2.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
 - 2.2.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Type (2021-2026)
 - 2.2.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026)
- 2.3 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Vaccine Valency
 - 2.3.1 Single Vaccine
 - 2.3.2 Dual Vaccine
 - 2.3.3 Others
 - 2.3.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency
 - 2.3.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)

2.3.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Vaccine Valency (2021-2026)

2.3.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026)

2.4 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Dose Pack Size

2.4.1 Small Pack (Below 20 Doses per Vial)

2.4.2 Medium Pack (20-50 Doses per Vial)

2.4.3 Large Pack (Above 50 Doses per Vial)

2.4.4 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size

2.4.4.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)

2.4.4.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Dose Pack Size (2021-2026)

2.4.4.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026)

2.5 Swine Mycoplasma Hyopneumoniae Vaccine Segment by Application

2.5.1 Large-scale Pig Farming Groups

2.5.2 Breeding Pig Farms

2.5.3 Veterinary Service Providers

2.5.4 Others

2.5.5 Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application

2.5.5.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)

2.5.5.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Breakdown Data by Company

3.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Company (2021-2026)

3.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)

3.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Company (2021-2026)

3.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026)

3.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)

3.3 Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company

3.4 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Product Location Distribution

3.4.2 Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION

4.1 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Geographic Region (2021-2026)

4.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Swine Mycoplasma Hyopneumoniae Vaccine Market Size by Country/Region (2021-2026)

4.2.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales by Country/Region (2021-2026)

4.2.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue by Country/Region (2021-2026)

4.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth

4.4 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth

4.5 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth

4.6 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth

5 AMERICAS

5.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country

5.1.1 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)

5.1.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country
(2021-2026)

5.2 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

5.3 Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application
(2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region

6.1.1 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region
(2021-2026)

6.1.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region
(2021-2026)

6.2 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

6.3 APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application
(2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine by Country

7.1.1 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country
(2021-2026)

7.1.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country
(2021-2026)

7.2 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

7.3 Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application
(2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine by Country

8.1.1 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026)

8.1.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026)

8.2 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026)

8.3 Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine

10.3 Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine

10.4 Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Swine Mycoplasma Hyopneumoniae Vaccine Distributors
- 11.3 Swine Mycoplasma Hyopneumoniae Vaccine Customer

12 WORLD FORECAST REVIEW FOR SWINE MYCOPLASMA HYOPNEUMONIAE VACCINE BY GEOGRAPHIC REGION

- 12.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Market Size Forecast by Region
 - 12.1.1 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Region (2027-2032)
 - 12.1.2 Global Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)
- 12.4 Europe Forecast by Country (2027-2032)
- 12.5 Middle East & Africa Forecast by Country (2027-2032)
- 12.6 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Type (2027-2032)
- 12.7 Global Swine Mycoplasma Hyopneumoniae Vaccine Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

- 13.1 Zoetis
 - 13.1.1 Zoetis Company Information
 - 13.1.2 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.1.3 Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.1.4 Zoetis Main Business Overview
 - 13.1.5 Zoetis Latest Developments
- 13.2 Boehringer Ingelheim
 - 13.2.1 Boehringer Ingelheim Company Information
 - 13.2.2 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.2.3 Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.2.4 Boehringer Ingelheim Main Business Overview
- 13.2.5 Boehringer Ingelheim Latest Developments
- 13.3 Merck Animal Health
 - 13.3.1 Merck Animal Health Company Information
 - 13.3.2 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.3.3 Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.3.4 Merck Animal Health Main Business Overview
 - 13.3.5 Merck Animal Health Latest Developments
- 13.4 Ceva Sant? Animale
 - 13.4.1 Ceva Sant? Animale Company Information
 - 13.4.2 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.4.3 Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.4.4 Ceva Sant? Animale Main Business Overview
 - 13.4.5 Ceva Sant? Animale Latest Developments
- 13.5 HIPRA
 - 13.5.1 HIPRA Company Information
 - 13.5.2 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.5.3 HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.5.4 HIPRA Main Business Overview
 - 13.5.5 HIPRA Latest Developments
- 13.6 Bioveta
 - 13.6.1 Bioveta Company Information
 - 13.6.2 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.6.3 Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.6.4 Bioveta Main Business Overview
 - 13.6.5 Bioveta Latest Developments
- 13.7 Vaxxinova
 - 13.7.1 Vaxxinova Company Information
 - 13.7.2 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.7.3 Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price

and Gross Margin (2021-2026)

13.7.4 Vaxxinova Main Business Overview

13.7.5 Vaxxinova Latest Developments

13.8 Nisseiken

13.8.1 Nisseiken Company Information

13.8.2 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

13.8.3 Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Nisseiken Main Business Overview

13.8.5 Nisseiken Latest Developments

13.9 Kyoto Biken Laboratories

13.9.1 Kyoto Biken Laboratories Company Information

13.9.2 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

13.9.3 Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Kyoto Biken Laboratories Main Business Overview

13.9.5 Kyoto Biken Laboratories Latest Developments

13.10 Pulike Biological Engineering

13.10.1 Pulike Biological Engineering Company Information

13.10.2 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

13.10.3 Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Pulike Biological Engineering Main Business Overview

13.10.5 Pulike Biological Engineering Latest Developments

13.11 Wuhan Keqian Biology

13.11.1 Wuhan Keqian Biology Company Information

13.11.2 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

13.11.3 Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.11.4 Wuhan Keqian Biology Main Business Overview

13.11.5 Wuhan Keqian Biology Latest Developments

13.12 Qilu Animal Health

13.12.1 Qilu Animal Health Company Information

13.12.2 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

- 13.12.3 Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.12.4 Qilu Animal Health Main Business Overview
- 13.12.5 Qilu Animal Health Latest Developments
- 13.13 Huapai Biotechnology
 - 13.13.1 Huapai Biotechnology Company Information
 - 13.13.2 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.13.3 Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 Huapai Biotechnology Main Business Overview
 - 13.13.5 Huapai Biotechnology Latest Developments
- 13.14 TianKang Pharmaceutical
 - 13.14.1 TianKang Pharmaceutical Company Information
 - 13.14.2 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.14.3 TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 TianKang Pharmaceutical Main Business Overview
 - 13.14.5 TianKang Pharmaceutical Latest Developments
- 13.15 Jinyu Bio-technology
 - 13.15.1 Jinyu Bio-technology Company Information
 - 13.15.2 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.15.3 Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.15.4 Jinyu Bio-technology Main Business Overview
 - 13.15.5 Jinyu Bio-technology Latest Developments
- 13.16 Zhaofenghua Bio-technology
 - 13.16.1 Zhaofenghua Bio-technology Company Information
 - 13.16.2 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
 - 13.16.3 Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.16.4 Zhaofenghua Bio-technology Main Business Overview
 - 13.16.5 Zhaofenghua Bio-technology Latest Developments
- 13.17 Yunnan Biopharmaceutical
 - 13.17.1 Yunnan Biopharmaceutical Company Information
 - 13.17.2 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine

Product Portfolios and Specifications

13.17.3 Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine
Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Yunnan Biopharmaceutical Main Business Overview

13.17.5 Yunnan Biopharmaceutical Latest Developments

13.18 Yangzhou Uni-Bio Pharmaceutical

13.18.1 Yangzhou Uni-Bio Pharmaceutical Company Information

13.18.2 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae
Vaccine Product Portfolios and Specifications

13.18.3 Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae
Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Yangzhou Uni-Bio Pharmaceutical Main Business Overview

13.18.5 Yangzhou Uni-Bio Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Swine Mycoplasma Hyopneumoniae Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Inactivated Vaccine
- Table 4. Major Players of Live Attenuated Vaccine
- Table 5. Major Players of Others
- Table 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)
- Table 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)
- Table 8. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Type (2021-2026) & (\$ million)
- Table 9. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
- Table 10. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Type (2021-2026) & (US\$/Dose)
- Table 11. Major Players of Single Vaccine
- Table 12. Major Players of Dual Vaccine
- Table 13. Major Players of Others
- Table 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Vaccine Valency (2021-2026) & (K Dose)
- Table 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency (2021-2026)
- Table 16. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Vaccine Valency (2021-2026) & (\$ million)
- Table 17. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
- Table 18. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Vaccine Valency (2021-2026) & (US\$/Dose)
- Table 19. Major Players of Small Pack (Below 20 Doses per Vial)
- Table 20. Major Players of Medium Pack (20-50 Doses per Vial)
- Table 21. Major Players of Large Pack (Above 50 Doses per Vial)
- Table 22. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Dose Pack Size (2021-2026) & (K Dose)

Table 23. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size (2021-2026)

Table 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Dose Pack Size (2021-2026) & (\$ million)

Table 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Dose Pack Size (2021-2026)

Table 26. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Dose Pack Size (2021-2026) & (US\$/Dose)

Table 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale by Application (2021-2026) & (K Dose)

Table 28. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2021-2026)

Table 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Application (2021-2026) & (\$ million)

Table 30. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application (2021-2026)

Table 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Application (2021-2026) & (US\$/Dose)

Table 32. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company (2021-2026) & (K Dose)

Table 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company (2021-2026)

Table 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company (2021-2026) & (\$ millions)

Table 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company (2021-2026)

Table 36. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Price by Company (2021-2026) & (US\$/Dose)

Table 37. Key Manufacturers Swine Mycoplasma Hyopneumoniae Vaccine Producing Area Distribution and Sales Area

Table 38. Players Swine Mycoplasma Hyopneumoniae Vaccine Products Offered

Table 39. Swine Mycoplasma Hyopneumoniae Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 40. New Products and Potential Entrants

Table 41. Market M&A Activity & Strategy

Table 42. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021-2026) & (K Dose)

Table 43. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Geographic Region (2021-2026)

Table 44. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 45. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region (2021-2026)

Table 46. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country/Region (2021-2026) & (K Dose)

Table 47. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021-2026)

Table 48. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country/Region (2021-2026) & (\$ millions)

Table 49. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country/Region (2021-2026)

Table 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)

Table 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 54. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 55. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Region (2021-2026) & (K Dose)

Table 56. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region (2021-2026)

Table 57. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Region (2021-2026) & (\$ millions)

Table 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 60. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 61. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Country (2021-2026) & (\$ millions)

Table 62. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 63. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application

(2021-2026) & (K Dose)

Table 64. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Country (2021-2026) & (K Dose)

Table 65. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Table 66. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Type (2021-2026) & (K Dose)

Table 67. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales by Application (2021-2026) & (K Dose)

Table 68. Key Market Drivers & Growth Opportunities of Swine Mycoplasma Hyopneumoniae Vaccine

Table 69. Key Market Challenges & Risks of Swine Mycoplasma Hyopneumoniae Vaccine

Table 70. Key Industry Trends of Swine Mycoplasma Hyopneumoniae Vaccine

Table 71. Swine Mycoplasma Hyopneumoniae Vaccine Raw Material

Table 72. Key Suppliers of Raw Materials

Table 73. Swine Mycoplasma Hyopneumoniae Vaccine Distributors List

Table 74. Swine Mycoplasma Hyopneumoniae Vaccine Customer List

Table 75. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 76. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 77. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 78. Americas Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 79. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Region (2027-2032) & (K Dose)

Table 80. APAC Swine Mycoplasma Hyopneumoniae Vaccine Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 81. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 82. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 83. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Country (2027-2032) & (K Dose)

Table 84. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 85. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Type

(2027-2032) & (K Dose)

Table 86. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 87. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Forecast by Application (2027-2032) & (K Dose)

Table 88. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 89. Zoetis Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 90. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 91. Zoetis Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 92. Zoetis Main Business

Table 93. Zoetis Latest Developments

Table 94. Boehringer Ingelheim Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 95. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 96. Boehringer Ingelheim Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 97. Boehringer Ingelheim Main Business

Table 98. Boehringer Ingelheim Latest Developments

Table 99. Merck Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 100. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 101. Merck Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 102. Merck Animal Health Main Business

Table 103. Merck Animal Health Latest Developments

Table 104. Ceva Sant? Animale Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 105. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 106. Ceva Sant? Animale Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 107. Ceva Sant? Animale Main Business

Table 108. Ceva Sant? Animale Latest Developments

Table 109. HIPRA Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 110. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 111. HIPRA Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 112. HIPRA Main Business

Table 113. HIPRA Latest Developments

Table 114. Bioveta Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 115. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 116. Bioveta Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 117. Bioveta Main Business

Table 118. Bioveta Latest Developments

Table 119. Vaxxinova Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 120. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 121. Vaxxinova Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 122. Vaxxinova Main Business

Table 123. Vaxxinova Latest Developments

Table 124. Nisseiken Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 125. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 126. Nisseiken Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 127. Nisseiken Main Business

Table 128. Nisseiken Latest Developments

Table 129. Kyoto Biken Laboratories Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 130. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications

Table 131. Kyoto Biken Laboratories Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 132. Kyoto Biken Laboratories Main Business

Table 133. Kyoto Biken Laboratories Latest Developments
Table 134. Pulike Biological Engineering Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 136. Pulike Biological Engineering Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 137. Pulike Biological Engineering Main Business
Table 138. Pulike Biological Engineering Latest Developments
Table 139. Wuhan Keqian Biology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 141. Wuhan Keqian Biology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 142. Wuhan Keqian Biology Main Business
Table 143. Wuhan Keqian Biology Latest Developments
Table 144. Qilu Animal Health Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 146. Qilu Animal Health Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 147. Qilu Animal Health Main Business
Table 148. Qilu Animal Health Latest Developments
Table 149. Huapai Biotechnology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 150. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 151. Huapai Biotechnology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 152. Huapai Biotechnology Main Business
Table 153. Huapai Biotechnology Latest Developments
Table 154. TianKang Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 155. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 156. TianKang Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 157. TianKang Pharmaceutical Main Business
Table 158. TianKang Pharmaceutical Latest Developments
Table 159. Jinyu Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 160. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 161. Jinyu Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 162. Jinyu Bio-technology Main Business
Table 163. Jinyu Bio-technology Latest Developments
Table 164. Zhaofenghua Bio-technology Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 165. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 166. Zhaofenghua Bio-technology Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 167. Zhaofenghua Bio-technology Main Business
Table 168. Zhaofenghua Bio-technology Latest Developments
Table 169. Yunnan Biopharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 170. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 171. Yunnan Biopharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 172. Yunnan Biopharmaceutical Main Business
Table 173. Yunnan Biopharmaceutical Latest Developments
Table 174. Yangzhou Uni-Bio Pharmaceutical Basic Information, Swine Mycoplasma Hyopneumoniae Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 175. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Product Portfolios and Specifications
Table 176. Yangzhou Uni-Bio Pharmaceutical Swine Mycoplasma Hyopneumoniae Vaccine Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)
Table 177. Yangzhou Uni-Bio Pharmaceutical Main Business
Table 178. Yangzhou Uni-Bio Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Swine Mycoplasma Hyopneumoniae Vaccine
- Figure 2. Swine Mycoplasma Hyopneumoniae Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Growth Rate 2021-2032 (K Dose)
- Figure 7. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2025)
- Figure 10. Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Inactivated Vaccine
- Figure 12. Product Picture of Live Attenuated Vaccine
- Figure 13. Product Picture of Others
- Figure 14. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type in 2026
- Figure 15. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Type (2021-2026)
- Figure 16. Product Picture of Single Vaccine
- Figure 17. Product Picture of Dual Vaccine
- Figure 18. Product Picture of Others
- Figure 19. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Vaccine Valency in 2026
- Figure 20. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Vaccine Valency (2021-2026)
- Figure 21. Product Picture of Small Pack (Below 20 Doses per Vial)
- Figure 22. Product Picture of Medium Pack (20?50 Doses per Vial)
- Figure 23. Product Picture of Large Pack (Above 50 Doses per Vial)
- Figure 24. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Dose Pack Size in 2026
- Figure 25. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share

by Dose Pack Size (2021-2026)

Figure 26. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Large-scale Pig Farming Groups

Figure 27. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Large-scale Pig Farming Groups (2021-2026) & (K Dose)

Figure 28. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Breeding Pig Farms

Figure 29. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Breeding Pig Farms (2021-2026) & (K Dose)

Figure 30. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Veterinary Service Providers

Figure 31. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Veterinary Service Providers (2021-2026) & (K Dose)

Figure 32. Swine Mycoplasma Hyopneumoniae Vaccine Consumed in Others

Figure 33. Global Swine Mycoplasma Hyopneumoniae Vaccine Market: Others (2021-2026) & (K Dose)

Figure 34. Global Swine Mycoplasma Hyopneumoniae Vaccine Sale Market Share by Application (2025)

Figure 35. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Application in 2025

Figure 36. Swine Mycoplasma Hyopneumoniae Vaccine Sales by Company in 2025 (K Dose)

Figure 37. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Company in 2025

Figure 38. Swine Mycoplasma Hyopneumoniae Vaccine Revenue by Company in 2025 (\$ millions)

Figure 39. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Company in 2025

Figure 40. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Geographic Region (2021-2026)

Figure 41. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Geographic Region in 2025

Figure 42. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 43. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 44. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 45. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$

millions)

Figure 46. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 47. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 48. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales 2021-2026 (K Dose)

Figure 49. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue 2021-2026 (\$ millions)

Figure 50. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025

Figure 51. Americas Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Figure 52. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 53. Americas Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 54. United States Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 55. Canada Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 56. Mexico Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 57. Brazil Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 58. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Region in 2025

Figure 59. APAC Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Region (2021-2026)

Figure 60. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 61. APAC Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 62. China Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 63. Japan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 64. South Korea Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 65. Southeast Asia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 66. India Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 67. Australia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 68. China Taiwan Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 69. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country in 2025

Figure 70. Europe Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share by Country (2021-2026)

Figure 71. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 72. Europe Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 73. Germany Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 74. France Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 75. UK Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 76. Italy Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 77. Russia Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 78. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Country (2021-2026)

Figure 79. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Type (2021-2026)

Figure 80. Middle East & Africa Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share by Application (2021-2026)

Figure 81. Egypt Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 82. South Africa Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 83. Israel Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 84. Turkey Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth

2021-2026 (\$ millions)

Figure 85. GCC Countries Swine Mycoplasma Hyopneumoniae Vaccine Revenue Growth 2021-2026 (\$ millions)

Figure 86. Manufacturing Cost Structure Analysis of Swine Mycoplasma Hyopneumoniae Vaccine in 2026

Figure 87. Manufacturing Process Analysis of Swine Mycoplasma Hyopneumoniae Vaccine

Figure 88. Industry Chain Structure of Swine Mycoplasma Hyopneumoniae Vaccine

Figure 89. Channels of Distribution

Figure 90. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Forecast by Region (2027-2032)

Figure 91. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Region (2027-2032)

Figure 92. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Type (2027-2032)

Figure 93. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Type (2027-2032)

Figure 94. Global Swine Mycoplasma Hyopneumoniae Vaccine Sales Market Share Forecast by Application (2027-2032)

Figure 95. Global Swine Mycoplasma Hyopneumoniae Vaccine Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Swine Mycoplasma Hyopneumoniae Vaccine Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G71A0E0E4313EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G71A0E0E4313EN.html>